4/A: Incyte Corp: Executive Earns Performance Shares

Incyte Corporation's CMO, Steven H. Stein, has been awarded 44,124 performance shares based on achieved performance criteria, with vesting scheduled for July 2026.

Summary

• Steven H. Stein, Chief Marketing Officer & Head of Late-Stage Development at Incyte Corporation, has had performance shares certified as earned.
• A total of 44,124 performance shares were awarded, with the determination of earned criteria made on May 6, 2026.
• These shares are set to vest on the third anniversary of their grant date, July 14, 2023, provided Mr. Stein remains employed by Incyte.
• The performance criteria were based on specified development, revenue, and market-based goals, including relative total shareholder returns compared to the Nasdaq Biotechnology Index.
• This filing is an amendment to a previous Form 4 filed on April 17, 2026, to reflect the updated determination of earned performance shares.
• Mr. Stein also beneficially owns an aggregate of 78,327 shares of common stock from previously reported restricted stock units and unvested performance shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating that an executive has met performance targets, which is a standard part of compensation and corporate governance.

Positives

• Achievement of performance criteria for 44,124 performance shares by a key executive.
• Confirmation of earned performance shares indicates successful progress towards company goals.
• The executive's continued employment is a positive sign for leadership stability.

Negatives

• The performance shares are subject to continued service, meaning they could be forfeited if the executive leaves before vesting.
• The vesting is contingent on continued service until the third anniversary of the grant date (July 14, 2026).

Risks

• Potential forfeiture of earned performance shares if Steven H. Stein's employment with Incyte terminates before July 14, 2026.
• The number of shares ultimately received can range from 0% to 150% of the awarded performance shares, indicating variability in final payout.

Future Outlook

The performance shares awarded to Steven H. Stein are scheduled to vest on the third anniversary of the grant date, July 14, 2026, contingent upon his continued service with Incyte Corporation. The final number of shares received may vary between 0% and 150% of the awarded performance shares based on specified performance goals.

Management Comments

• The performance shares are subject to specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals.
• The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded.

Industry Context

StockSavvy.ai notes that the awarding and vesting of performance shares tied to development, revenue, and market-based goals is a common practice in the biotechnology sector to incentivize executive performance and align their interests with shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: The achievement of performance goals by executives can be seen as a positive indicator of company progress, potentially aligning with long-term shareholder value.
• Employees: The structure of executive compensation can influence overall employee morale and retention strategies.
• Management: Confirms the achievement of specific performance metrics set by the Compensation Committee, reinforcing accountability.

Next Steps

• Vesting of 44,124 performance shares on July 14, 2026, subject to continued employment.
• Potential adjustment of the number of shares received based on performance outcomes over the three-year period.

Key Dates

Keywords

Incyte Corporation, Form 4, SEC Filing, Performance Shares, Stock Options, Executive Compensation, Beneficial Ownership, Steven H. Stein, Vesting, Biotechnology